SCPS (Scopus BioPharma) Inventories, Finished Goods: $0.00 Mil (As of Jun. 2023)


What is Scopus BioPharma Inventories, Finished Goods?

Scopus BioPharma SCPS Inventories, Finished Goods is $0.00 Mil as of Jun. 2023.

Scopus BioPharma Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Scopus BioPharma's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scopus BioPharma Inventories, Finished Goods Chart

Scopus BioPharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Inventories, Finished Goods
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Scopus BioPharma Quarterly Data
Jun18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Scopus BioPharma Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of $0.00 Mil mean?
Scopus BioPharma (SCPS) has a Inventories, Finished Goods of $0.00 Mil as of Jun. 2023. Finished goods are inventory items that are complete and ready to be sold. View historical data on Scopus BioPharma and its competitors.
Is Scopus BioPharma's Inventories, Finished Goods too high?
Scopus BioPharma's current Inventories, Finished Goods is $0.00 Mil.
How does Scopus BioPharma's Inventories, Finished Goods compare to AMPE and DRMA?
Scopus BioPharma's Inventories, Finished Goods of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Scopus BioPharma and its competitors. Scopus BioPharma's current Inventories, Finished Goods is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scopus BioPharma stock overvalued right now?
Scopus BioPharma (SCPS) has a current Inventories, Finished Goods of $0.00 Mil. The current Inventories, Finished Goods is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Scopus BioPharma (SCPS), the current Inventories, Finished Goods is $0.00 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scopus BioPharma Business Description

Address 420 Lexington Avenue, Suite 300, New York, NY, USA, 10170
Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.